A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children With Hemodynamically Significant Congenital Heart Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children With Hemodynamically Significant Congenital Heart Disease
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
The primary objective was to describe the safety and tolerability of motavizumab when given monthly as prophylaxis against serious RSV infection among children with hemodynamically significant congenital heart disease.
Inclusion Criteria:
Exclusion Criteria:
Wein, Austria
Brussells, 1090, Belgium
Saskatoon SK, Canada
Plzen - Lochotin, 304 60, Czechia
Århus N, DK-8200, Denmark
Achrafieh- Beirut, Lebanon
Bydgoszcz, 85-168, Poland
Szczecin, 71-252, Poland
Esplugas de Llobregat, 08950, Spain